August 1, 2020

Treventis attends Virtual AAIC 2020

Treventis was well represented at the Alzheimer Association International Conference, running from Jul 27-31, 2020 (originally scheduled for Amsterdam, the…

Read More

July 8, 2020

Treventis founders awarded funding for COVID-19 clinical trial

LifeArc, a major UK-based charity, has announced funding for Treventis founders Dr. Donald Weaver, Christopher Barden, and Mark Reed to…

Read More

June 13, 2020

Treventis attends Virtual BIO Conference

Not to be deterred by COVID-19, Treventis attended the BIO Digital International Convention (formerly scheduled for San Diego, California; instead…

Read More

February 25, 2020

Treventis attends 8th Neurodegenerative Drug Development Summit

Treventis CSO Mark Reed was in attendance at the 8th Neurodegenerative Drug Development Summit (previously known as World CNS) held…

Read More

February 12, 2020

Treventis Attends Tau2020 Conference

Treventis VP Research Marcia Taylor has attended Tau2020 in Washington, DC, which is one of the world’s biggest conferences focusing…

Read More

December 13, 2019

Treventis founders publish new computational methodology for brain drug design

Treventis founders Dr. Donald Weaver, Mark Reed, and Christopher Barden have supervised research at Toronto hospital UHN into new methods…

Read More

[siteorigin_widget class=”WP_Widget_Custom_HTML”][/siteorigin_widget]

Share this page

#pf-body .pf-caption img.blockImage { margin: 0!important; float: none; } #pf-body a.elementor-icon, #pf-body a.skip-link{display:none!important;} /*#pf-content {max-width:100%!important}*/ #pf-content img.mediumImage, #pf-content figure.mediumImage { margin-left: auto!important; margin-right: auto!important; clear: both!important; float: none!important; display: block!important; }